The significance of eosinophil and eosinophil lymphocyte ratio (ELR) in predicting response to omalizumab treatment in patients with severe allergic asthma
- PMID: 33853304
- DOI: 10.5578/tt.20219905
The significance of eosinophil and eosinophil lymphocyte ratio (ELR) in predicting response to omalizumab treatment in patients with severe allergic asthma
Abstract
Introduction: Th2/Th1 mix pathological pathway may be seen as a common set of low eosinophilic phenotype in severe allergic asthma. This may affect omalizumab treatment response. In our study, we aimed to investigate whether eosinophil count (EOS) and percentage (EOS%), eosinophil lymphocyte ratio (ELR) and neutrophil lymphocyte ratio (NLR) may predict omalizumab treatment.
Materials and methods: Patients who received omalizumab treatment at least for one year in our allergy clinic were screened retrospectively. Baseline hemogram parameters, pre- and post-treatment emergency admissions, annual attacks requiring steroid use, hospitalizations, spirometric changes, and asthma control tests (ACT) were recorded. According the global efficacy assessment (phisician's GETE) scale patients was recorded as responder and nonresponder. By looking at EOS, EOS%, ELR and NLR distributions in these groups, the role of these parameters in representation of the treatment efficacy was investigated.
Result: The study was carried out with 83 patients, 77.1% of whom were women with an average age of 50.03 ± 10.7. While ACT scores and FEV1, FEF25-75 was significantly increased, the number of emergency admissions, annual attacks and hospitalizations decreased significantly (p<0.05). The rate of patients signed as responder was 75.9%, while the rate of nonresponder was %24.1. When the two groups were compared, it was found that the EOS, EOS% and ELR were significantly higher in the responder group. The cut-off values according to the ROC curve were determined as 0.12, 310/ml and 3.1% respectively. Considering the sensitivity (58.73%); specificity (85.00%); positive predictive value (92.50%), it was determined that ELR was a more valuable test.
Conclusions: Instead of expensive and invasive methods for predicting the response of omalizumab therapy in severe allergic asthma, the ELR is correlated with treatment response and giving hope to be easier way to reach.
Similar articles
-
Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study.J Asthma. 2023 Oct;60(10):1862-1868. doi: 10.1080/02770903.2023.2196562. Epub 2023 Apr 21. J Asthma. 2023. PMID: 36971065
-
Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.Clin Ther. 2019 Oct;41(10):1956-1971. doi: 10.1016/j.clinthera.2019.07.021. Epub 2019 Sep 25. Clin Ther. 2019. PMID: 31563391
-
Eosinophil to lymphocyte ratio may predict OCS reduction and change in quality of life (AQLQ) resulting from asthma biological treatment.Immunopharmacol Immunotoxicol. 2024 Apr;46(2):212-217. doi: 10.1080/08923973.2023.2300300. Epub 2024 Jan 22. Immunopharmacol Immunotoxicol. 2024. PMID: 38151952
-
Biomarkers for severe allergic asthma in children: could they be useful to guide disease control and use of omalizumab?Expert Rev Respir Med. 2018 Jun;12(6):475-482. doi: 10.1080/17476348.2018.1475233. Epub 2018 May 16. Expert Rev Respir Med. 2018. PMID: 29741411 Review.
-
The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.Pneumonol Alergol Pol. 2016;84(4):232-43. doi: 10.5603/PiAP.2016.0029. Pneumonol Alergol Pol. 2016. PMID: 27435350 Review.
Cited by
-
The Significance of Eosinophil-to-Lymphocyte Ratio in Predicting Response to Omalizumab Treatment in Patients with Bullous Pemphigoid: A Case Series.Indian J Dermatol. 2024 Jan-Feb;69(1):81-85. doi: 10.4103/ijd.ijd_236_23. Epub 2024 Feb 27. Indian J Dermatol. 2024. PMID: 38572025 Free PMC article.
-
Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives.Front Immunol. 2023 Jun 2;14:1207641. doi: 10.3389/fimmu.2023.1207641. eCollection 2023. Front Immunol. 2023. PMID: 37334374 Free PMC article. Review.
-
Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors.Biomedicines. 2021 Oct 19;9(10):1497. doi: 10.3390/biomedicines9101497. Biomedicines. 2021. PMID: 34680614 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical